The Technical Analyst
Mediwound Ltd [MDWD]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Mediwound Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.28% $18.24
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 173.13 mill |
| EPS: | -0.750 |
| P/E: | -24.32 |
| Earnings Date: | May 28, 2024 |
| SharesOutstanding: | 9.49 mill |
| Avg Daily Volume: | 0.0738 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -24.32 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -4.14x |
| Company: PE -24.32 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-5.73 (-131.43%) $-23.97 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 17.43 - 19.05 ( +/- 4.46%) |
| ATR Model: 14 days |
Forecast:
16:00 - $18.17
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $18.17
Forecast 2: 16:00 - $18.17
Forecast 3: 16:00 - $18.17
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $18.24 (3.28% ) |
| Volume | 0.0730 mill |
| Avg. Vol. | 0.0738 mill |
| % of Avg. Vol | 98.94 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MDWD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Latest Press Releases
2024-04-25 08:00:00 - Press Release
Mediwound To Present New Data From Escharex® Phase Ii Studies At Three Leading Wound Care Conferences
Oral presentations include additional comparative data between escharex ® and santyl ® , and new analyses show strong correlation between wound bed preparation and wound healing
2024-03-21 07:00:00 - Press Release
Mediwound Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Company Update
$19 million revenue in 2023; $24 million projected revenue in 2024 nexobrid ® commercially launched in u.s., japan, india potential blockbuster escharex ® to begin phase iii in the second half of 2024 $42 million cash runway through profitability
2024-03-14 08:00:00 - Press Release
Mediwound To Report Fourth Quarter And Full Year 2023 Financial Results
Conference call and webcast scheduled for thursday, march 21st at 8:30 am eastern time conference call and webcast scheduled for thursday, march 21st at 8:30 am eastern time
2024-02-12 07:00:00 - Press Release
Mediwound Announces Positive Results In Head-to-head Comparison Of Escharex® Vs. Santyl® Within The Chronex Phase Ii Randomized Controlled Study
Results demonstrate superiority of escharex®, a bromelain-based gel vs. santyl®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (vlu) results demonstrate superiority of escharex®, a bromelain-based gel vs. santyl®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (vlu)
2024-02-05 08:00:00 - Press Release
Mediwound To Participate In Two Upcoming Investor Conferences
Yavne, israel, feb. 05, 2024 (globe newswire) -- mediwound ltd. (nasdaq: mdwd), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming oppenheimer 34th annual life sciences conference, taking place virtually on february 13-14, 2024, as well as the upcoming td cowen 44th annual health care conference, taking place in boston on march 4-6, 2024.
Latest News
2024-04-17 08:26:06 - Zacks Investment Research
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-03-25 10:56:08 - Zacks Investment Research
Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?
The mean of analysts' price targets for MediWound (MDWD) points to a 76.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-03-25 09:51:10 - Zacks Investment Research
What Makes MediWound (MDWD) a Good Fit for 'Trend Investing'
MediWound (MDWD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
2024-03-21 09:26:03 - Zacks Investment Research
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $1.18 per share a year ago.
2024-03-14 08:00:00 - GlobeNewsWire
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time
2024-03-06 09:51:13 - Zacks Investment Research
MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-01-09 19:33:55 - Zacks Investment Research
Wall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a Bet
The consensus price target hints at a 134.8% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-01-09 10:31:29 - Zacks Investment Research
MediWound (MDWD): Strong Industry, Solid Earnings Estimate Revisions
MediWound (MDWD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2023-11-27 11:17:53 - Zacks Investment Research
Does MediWound (MDWD) Have the Potential to Rally 223.05% as Wall Street Analysts Expect?
The consensus price target hints at a 223.1% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2023-11-14 08:02:00 - GlobeNewsWire
MediWound to Report Third Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time